Drug Profile
Olmesartan medoxomil/amlodipine/hydrochlorothiazide - Daiichi Sankyo
Alternative Names: CS-8635; Sevikar HCT; Sevikar Plus; TribenzorLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Daewoong Pharmaceutical; Daiichi Sankyo Company
- Class Antihypertensives; Benzothiadiazines; Dihydropyridines; Imidazoles; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 18 Jan 2022 Olmesartan medoxomil/amlodipine/hydrochlorothiazide licensed to Cosette Pharmaceuticals in USA
- 10 Jan 2019 Chemical structure information added
- 31 Dec 2018 Sungkyunkwan University School of Medicine and Daiichi Sankyo completes the phase III trial in Hypertension in South Korea (PO) (ISRCTN51756760)